Trade Margin Rationalisation offers a market-friendly alternative to ceiling-price control in India's drug pricing. Critically examine with reference to anti-cancer medicines.

Ceiling-price control fixes the actual price of medicines in the National List of Essential Medicines, which forms Schedule-I of DPCO 2013 [2]. Trade Margin Rationalisation (TMR) works differently: it limits only the mark-up added by distributors and retailers. Using Para 19 of DPCO 2013, NPPA has capped trade margins at 30% of MRP on 137 non-scheduled anti-cancer drugs [1]. TMR is more market-friendly than ceiling prices, but it does not yet replace them.

Strengths: why TMR is market-friendly

• Manufacturer pricing protected: it targets distribution margins "while safeguarding legitimate manufacturer revenues" [1].
• Proven results: the 2019 pilot on 42 drugs cut the MRP of 526 brands by up to 90%, about 50% on average, and saved patients about ₹984 crore a year [3].
• Reaches the uncovered market: non-scheduled drugs hold about 82% of the market and have no ceiling price [5]. TMR covers them without expanding the NLEM.
• Transparency: prices must be displayed at pharmacies and on hospital websites, and patients can check them on the Pharma Sahi Daam app [1].
• Supply safeguard: companies must keep production and supply at current levels [1].

Weaknesses: why it is not yet a full alternative

• Launch price untouched: the Standing Committee flagged that non-scheduled drugs can be launched at arbitrary prices [5]. A 30% cap on an inflated base still leaves a high MRP.
• "Up to 70%" is the best case: actual cuts depend on each drug's existing price structure [1].
• Ad hoc legal basis: Para 19 is an emergency power. It was even used in 2024 to raise ceiling prices of 8 drugs by 50% [4]. There is still no timeline for a permanent TMR framework in DPCO [5].
• Weak enforcement: ₹8,526 crore (85%) of overcharging demands is unrecovered, and about 70% of it is stuck in court cases [5]. State Drug Controllers must also check hospital bills, and hospitals supply many anti-cancer drugs [1].
• Supply risk untested: official releases report price cuts, not whether stock was available after the cut [3].

Way forward

• Write TMR into DPCO 2013, with objective criteria for choosing drugs [5].
• Review how drugs are classified, to curb unjustified launch prices [5].
• Set up an NPPA legal cell and a fast-track route for disputes [5].
• Publish brand-wise compliance and hospital availability data.

TMR therefore complements ceiling-price control rather than replacing it: it curbs profiteering in the supply chain and leaves the manufacturer's price to the market. If it is made permanent, rule-based and backed by State enforcement, it can make cancer care affordable. That would serve Article 47's duty to improve public health and SDG 3.8 on universal health coverage.